FDA AdCom strongly backs EUA of Novavax COVID-19 Vaccine

The US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) yesterday voted 21 to 0, with one abstention, to recommend that the FDA grant Emergency Use Authorization (EUA) for the Novavax COVID-19 vaccine (NVX-CoV2373) for individuals aged 18 years and over. The vaccine was developed by US biotech firm Novavax (Nasdaq: NVAX), whose shares leapt 22% to $58.05 in after-hours trading on Tuesday.